retatrutide clinical trial results 2025 Trials That Redefined Medicine in Retatrutide vs Ozempic: Clinical Trial

Washington, Towson, and throughout the greater Baltimore area who are navigating eating disorders, disordered eating, and the complex questions that arise when mental health and medical treatment intersect

FDA's April 30, 2026 Proposal On April 30, 2026, the FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound these drugs from bulk drug substances when FDA-approved versions are available

Use of gastric ultrasound may be prudent for high-risk patients presenting with symptoms of indigestion or nausea/vomiting, however its utility in high-turnover, low resource settings is limited

Your physician will determine if retatrutide is medically appropriate for you